Antibiotics are used for fighting pathogens, but also target our commensal bacteria as a side 25 effect, disturbing the gut microbiota composition and causing dysbiosis and disease 1-3 .
(ranging from 5 to 24 hours), the number of colony forming units (CFU)/ml of culture 139 decreases by more than 99.9%, the antibiotic is considered bactericidal 40 . We assessed the 148 coli, we were surprised to see that doxycycline effectively killed the commensal E. coli ED1a 149 ( Fig. 2a ). We verified that these effects held also in the presence of oxygen (Extended Data 150 Fig. 7a ) and confirmed that doxycycline has a stronger bactericidal action on this natural 151 isolate than on the domesticated E. coli K-12 lab strain, BW25113 (Extended Data Fig. 7b ).
152
In parallel, we excluded that the differences in killing capacity were confounded by growth 153 rate, growth phase or MIC of the bacterial species tested (Extended Data Fig. 8 ). We also 154 noticed that B. vulgatus and B. uniformis cultures decreased density in the presence of 155 erythromycin (Fig. 2d) . We confirmed by time-lapse microscopy that this was due to lysis.
156
Erythromycin caused cell shape defects, including blebbing, cytoplasmic shrinkage, and Prestwick library to identify antagonizing compounds to erythromycin or doxycycline on two 167 abundant and prevalent gut microbes, B. vulgatus and B. uniformis (Fig. 3a , Extended Data 168 Fig. 9 ). Of the 19 identified hits (Fig. 3b , Suppl. Table 4 ), we tested the 14 candidates with 169 the strongest activity in a concentration-dependent manner (Extended Data Fig. 10a ). Nine 170 retained antagonistic activity over a broader concentration range, which we confirmed by 171 checkerboard assays (Fig. 3c ). The antidotes that showed the strongest antagonisms were 172 the anticoagulant drug dicumarol, and two non-steroidal anti-inflammatory drugs, tolfenamic 173 acid and diflunisal. While dicumarol rescued B. vulgatus from erythromycin and diflunisal 174 from doxycycline, tolfenamic acid was able to protect B. vulgatus from both drugs. In 175 addition, these interactions were able to at least partially rescue the killing of B. vulgatus by 176 erythromycin and doxycycline (Extended Data Fig. 10b ). We then probed two of these drugs 177 for their ability to protect other abundant gut commensals and confirmed that both dicumarol 178 and tolfenamic acid were able to counteract erythromycin on several species (Fig. 3d Fig. 12b ). Altogether, our data provides 185 a proof-of-principle for identifying antidotes that specifically mask the collateral damage of 186 antibiotics on commensals. This concept would need to be further validated in the future in 187 animal models. Antidotes may also need to be modified to late (colon)-release or non-188 antibiotics on 50 different resident gut microbes down to the level of individual drugs, species 192 and partially even strains. We challenge the universal divide of antibiotics into bacteriostatic 193 and bactericidal across bacteria, as this breaks down when tested beyond model organisms.
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Antibiotics with preferential killing of some species may be the most detrimental to our gut 195 flora, although the first studies in a few healthy individuals point to the gut microbiota having 
207
Bacteria used in this study were typically pre-cultured for two overnights: Cells were cultured 213 in 5 ml modified Gifu Anaerobic Medium broth ( 
243
Estimates on the abundance and prevalence of species in the healthy human gut 244 microbiome were calculated using mOTUs v2 48 as follows: Relative species abundances 245 were determined in 727 shotgun metagenomic samples from donors in the control groups of 246 multiple studies from various countries and continents [49] [50] [51] [52] [53] . Prior to taxonomic profiling, 247 metagenomes were quality controlled using the MOCAT2 -rtf procedure 54 , which removed 248 reads with ≥95% sequence identity and an alignment length of ≥45bp to the human genome 249 hg19. Taxonomic profiles were then created using mOTUs version 2.1.0 48 with parameters -l 250 75 ; -g 2; and -c. Afterwards relative abundances below 10 -4 were set to zero and species 251 with nonzero abundance in <5 samples discarded. For the retained 1,350 species, 252 prevalence was defined as the percentage of samples with nonzero abundance; a 253 prevalence cut-off of 1% was chosen to classify species into "rare" and "common" species.
254
For all species in the MIC dataset, we manually assessed their status as pathogenic or non-255 pathogenic species using encyclopaedic and literature knowledge. Pathogenic species that 256 occur in more than 1% of healthy people (i.e. are designated as "common") were classified 257 as "potentially pathogenic species" that can, for example, cause diseases in 258 immunocompromised patients.
260
Killing curves and survival assay 261 Cells were precultured as described in the growth conditions section before being diluted to 262 an OD 578 =0.01 and grown for 2 h at 37°C (unless specified otherwise). Next, cells were cells were detected using this method, a bigger volume of culture (up to 2 ml) was plated to 268 be able to detect CFUs. Agar plates were incubated overnight at 37°C and colonies were 269 counted the next day, either manually, for low CFU numbers, or using the Analyze Particles concentration of each sample, and the analysis was stopped when 10,000 target events 287 were measured. Graphs were generated using the FlowJo V10.3 software (Treestar).
289
Microscopy 290 imaging, cells were precultured as described in the growth conditions section. Cells were 293 then diluted to an OD 578 =0.01 and grown for 3 h at 37°C before being spotted on MGAM 294 +1% agarose pads, supplemented or not with 15 µg/ml erythromycin (5-fold MIC) between a 295 glass slide and a coverslip. Slides were sealed with valap (to avoid/delay oxygen 296 permeation) and taken outside of the anaerobic chamber for imaging. In these conditions, 
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Analysis pipeline and hit calling. All growth curves within a plate were truncated at the 334 transition time from exponential to stationary phase and converted to normalized AUCs using 335 in-run control wells (no drug) as described before 4 .We then calculated z-scores based on 336 these normalized AUCs, removed replicates with 8-fold differences in z-scores to eliminate 337 noise effects, computed mean z-scores across the two replicates and selected combinations 338 with mean z-scores > 3. This selection included 19 potential antibiotic antagonists and we 339 followed up on 14 of them (7 potential erythromycin and 7 potential doxycycline antagonists In order to generate a phylogenetic tree for the different isolates, the nucleotide sequences 398 for a set of universally occurring, protein coding, single copy phylogenetic marker genes 48,58 399 were extracted from reference genomes or genome assemblies using fetchMG 58 400 (https://motu-tool.org/fetchMG.html). Within the framework of the ete3 toolkit 59 , independently and all columns with more than 10% gaps were removed. The individual 403 alignments were concatenated and finally, a phylogenetic tree was inferred from the 404 combined alignment using IQTree 61 . Supplementary Table 3 578 MICs as determined by MIC strips for selected antibiotics 579 Supplementary Table 4 580 Hitlist: Screen for microbiome-protective antagonists to erythromycin/tetracycline 581 Supplementary Table 5 582 Compounds used in this study lysis of B. vulgatus and B. uniformis. B. vulgatus and B . uniformis were grown for 3 hours before addition (yellow) or not (black) of 15 µg/ml ERY treatment (5-fold MIC; yellow) as indicated by the arrow. Growth curves were acquired for 20 hours. This graph shows the mean±SD (dotted line) of 3 independent experiments. e. Erythromycin induces blebbing, cytoplasmic shrinkage and lysis in B. vulgatus and B. uniformis. Phase contrast movies of B. vulgatus and B. uniformis were acquired after ERY treatment (5-fold MIC). Here shown 3 frames of 3 images per strain (time indicated in the upper left corner; t=0 when drug added). White arrows indicate blebs, cytoplasmic shrinkage and bacterial lysis; the scale bar is 5 µm. Movies are available in Supplementary  Material (Movies 1-4) . Schematic illustration of the screen concept: searching for antidote compounds that antagonize the antibacterial effect of erythromycin or doxycycline on commensal but not on pathogenic bacteria. b. Z-scores on bacterial growth (based on areas under the curve (AUCs)) for combinatorial drug exposure with antibiotic (ERY or DOX) and FDA-approved drug. Compounds that successfully rescued B. vulgatus and/or B. uniformis growth in the presence of the antibiotic (z-score > 3) are indicated in gray. The strongest hits (circles) were validated further in concentration-dependent assays (Extended Data Fig. 10a ). For each antibiotic and each strain, ~1200 drugs were tested in two replicates. Boxplots are defined as in Figure 1d . c. For 9 of the validated antagonists, 8 x 8 checkerboard assays were performed to determine concentration ranges of the antagonistic interaction. Heat maps depict bacterial growth based on normalized median of AUCs of 4 replicates. All interactions were antagonistic, and pairs tested further in other commensal species are framed in bold. d. Checkerboard assays confirm the ability of tolfenamic acid to protect further gut commensals from growth inhibition by erythromycin. Heat map as in c, but for 2 replicates. Antagonistic interactions are framed in red. e. Checkerboard of tolfenamic acid with erythromycin reveal neutral interactions in S. aureus and E. faecium (aerobic conditions). Heat maps as in c, based on at least two independent experiments with two technical replicates each. f. Tolfenamic acid concentration-dependent rescue of commensal growth at clinical relevant erythromycin concentrations based on AUCs (anaerobic conditions). Erythromycin still retains its activity against pertinent pathogens such as S. aureus, E. faecium and S. pneumoniae (aerobic conditions). 0.625 µM correspond to ~0.5 µg/ml erythromycin, which is in the range of the MIC breakpoints for Staphylococcus (1 µg/ml), S. pneumoniae (0.25 µg/ml) and Streptococci groups A, B, C & G (0.25 µg/ml). Error bars depict standard deviation.
Extended Data Figure 2 -MICs for 17 species on 35 antimicrobials
Heat map depicts MICs for each drug-strain pair in µg/ml. Heat map color gradient is adjusted to the MICs concentration range tested on the respective MIC test strip. Black depicts sensitivity and light grey indicates resistance. Mean values across two biological replicates are shown (Suppl. Table 3 ). C. difficile is particularly resistant to all tested macrolides and clindamycin (red box). Figure 3 -MIC dataset validates antibiotic sensitivity profiles from the screen dataset and is consistent with publically available MICs. a. Receiver operating characteristic (ROC) curve analysis was performed to evaluate sensitivity and specificity of the screen 4 using the MIC dataset. Results from the screen were considered as validated if MICs were below/above the 20 µM antibiotic concentration that was tested in the screen (allowing a two-fold error margin). N is the number of antibiotics that we tested both in the screen and determined MICs for, AUROC is the area under the characteristic ROC. TN denotes true negatives, FP false positives, TP true positives, FN false negatives. b. Comparison including Spearman correlation coefficients of the MICs from this study to MICs from the ChEMBL 27 and EUCAST 24 databases. Panels in the upper row: comparison between all MICs that are shared between the two indicated datasets. Panels in the lower row: comparison of the 69 MICs that are shared across all three datasets. Despite experimental differences, our MICs correlate well with available EUCAST/ ChEMBL data. c. Number of the sum of new (this study) and already available MICs (EUCAST/ ChEMBL) per drug according to antibiotic class and prevalence/virulence of the bacterial species. The new dataset expands MICs across the board and specifically fills the knowledge gap on nonpathogenic species. The left panel shows an overlay of phase contrast and fluorescence microscopy images of propidium iodide (PI)-stained E. coli ED1a before and 5 hours after ERY, AZI or DOX treatments. The number of cells on each frame has no meaning, as cultures were concentrated before imaging; the scale bar is 10 µM. The right panel shows the corresponding quantification of live/dead-stained cells by flow cytometry with Syto9 on the xaxis (live cells) and PI on the y-axis (dead cells). Both the total number of measured events (n) and the percentage of cells found in each quadrant are indicated on the graphs. Figure 7 -Effect of oxygen and strain specificity on survival after doxycycline treatment a. The survival of E. coli ED1a was assessed after a 5-hour treatment with 5-fold MIC of DOX in the presence or absence of oxygen. Killing was similarly effective in both conditions. b. The survival of E. coli ED1a and E. coli BW25113 were assessed after a 5-hour treatment with 1, 2 and 5-fold MIC of DOX in MGAM medium in anaerobic conditions. The lab strain is more resistant to killing with doxycycline becoming boarder-line bactericidal at higher MICs. Positive correlations for macrolides were tested further in b to check if changing growth rate in same species affects percentage killed. b. The survival of B. fragilis (blue) and F. nucleatum (beige) were assessed after a 5-hour macrolide treatment (5-fold MIC of ERY and AZI) at either 30°C (slow growth) or 37°C (fast growth) to test the effect of slowing down growth on survival. No significant change observed. This graph shows the mean±SD of three independent experiments. c. Scatter plot of MICs and percentage survival after a 5-hour treatment with 5-fold MIC of ERY, AZI or DOX treatments. r indicates the Spearman correlation coefficient. Doxycycline exhibited a strong and significant anti-correlation, that is that species which were more sensitive to doxycycline (lower MIC) were not killed when they were treated with 5-fold MIC concentrations. Thus, we tested further whether increasing the drug concentration in some of those sensitive strains decreased the % of survival (panel d). d. The survival of B. fragilis (blue) and F. nucleatum (beige) were assessed after a 5-hour treatment with increasing concentrations of DOX (5, 10 or 20-fold of MIC) to test whether higher concentrations of DOX induced more killing. This seemed not be the case. This graph shows the mean±SD of three independent experiments. e. To evaluate whether outgrowth of stationary phase and homogeneity of population affected our results, we selected two slow-growing strains, E. rectale and R. intestinalis and grew for 2 or 3 hours after being diluted from an overnight culture to an of OD578 0.01. Both strains were then treated for 5 hours with 5-fold MIC of ERY, AZI or DOX and their survival was assessed to test the impact of the growth phase on the percentage survival. Although slight differences were observed and 3h grown cultures were killed more effectively (presumably because more cells had exited stationary phase and were growing exponentially by then), the general trends remained the same. If anything, this means that we are underestimating the killing for slow-growers, since we performed all other experiments with 2 hours outgrowth. This graph shows the mean±SD of three independent experiments. f. The survival of 8 selected gut microbes was measured after treating cells in exponential phase (E -2 hours after dilution from an overnight culture) or in stationary phase (S -overnight growth) with 5-fold MIC of ERY for 5 hours to test the impact of the growth phase on the percentage survival. As expected, survival is higher in stationary phase for half of the strains, but in some cases stationary phase cells were as or more sensitive than exponentially growing cells -this is the case for B. caccae and F. nucleatum. This graph shows the mean±SD of three independent experiments. g. Same as in f but with DOX. Similar effects observed as in f, with more than half of strains becoming more resistant in stationary phase.
Extended Data

